Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Johnson and Johnson
Accenture
Cipla
Medtronic

Generated: May 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,396,841

« Back to Dashboard

Which drugs does patent 7,396,841 protect, and when does it expire?

Patent 7,396,841 protects PREVACID IV and is included in one NDA.

Protection for PREVACID IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has six patent family members in five countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,396,841
Title:Injections
Abstract:An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.
Inventor(s): Doen; Takayuki (Suita, JP), Nagao; Masao (Kashiba, JP), Asakawa; Naoki (Takatsuki, JP), Takechi; Nobuyuki (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/344,805
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,396,841
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Process; Use;

Drugs Protected by US Patent 7,396,841

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Na PREVACID IV lansoprazole INJECTABLE;INTRAVENOUS 021566-001 May 27, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,396,841

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-248468Aug 18, 2000
PCT Information
PCT FiledAugust 17, 2001PCT Application Number:PCT/JP01/07075
PCT Publication Date:February 28, 2002PCT Publication Number: WO02/15908

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
UBS
Queensland Health
Cantor Fitzgerald
Farmers Insurance
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.